ABSTRACT
Denosumab has been advocated as a potential treatment for the rare skeletal disorder fibrous dysplasia (FD); however, there is limited data to support safety and efficacy, particularly after drug discontinuation. We report a case of successful treatment of aggressive craniofacial FD with denosumab, highlighting novel insights into the duration of efficacy, surrogate treatment markers, and discontinuation effects. A 13-year-old girl presented with persistent pain and expansion of a maxillary FD lesion, which was not responsive to repeated surgical procedures or bisphosphonates. Pre-treatment biopsy showed high RANKL expression and localization with proliferation markers. Denosumab therapy was associated with improved pain, decreased bone turnover markers, and increased lesion density on computed tomography scan. During 3.5 years of treatment, the patient developed increased non-lesional bone density, and after denosumab discontinuation, she developed hypercalcemia managed with bisphosphonates. Pain relief and lesion stability continued for 2 years following treatment, and symptom recurrence coincided with increased bone turnover markers and decreased lesion density back to pre-treatment levels. This case highlights the importance of considering the duration of efficacy when treating patients with FD and other nonresectable skeletal neoplasms that require long-term management.
Subject(s)
Craniofacial Fibrous Dysplasia , Fibrous Dysplasia of Bone , Hypercalcemia , Adolescent , Denosumab/therapeutic use , Diphosphonates , Female , Fibrous Dysplasia of Bone/diagnostic imaging , Fibrous Dysplasia of Bone/drug therapy , HumansABSTRACT
Acute myelogenous leukemia (AML) accounts for about 20% of the acute leukemias seen in children. In contrast to childhood acute lymphoblastic leukemia (ALL), there has only been a modest improvement in the cure rate of children with AML during the past two decades. Approximately 40% of children treated with chemotherapy alone are long-term survivors. The outcome is somewhat better for those children who are given bone marrow transplants from histocompatible sibling donors early in the first remission. During the last decade, however, new insights into the molecular basis of AML has increased our understanding of the pathogenesis and biology of this group of leukemias and are beginning to provide us with new therapeutic strategies.
Subject(s)
Leukemia, Myeloid/diagnosis , Leukemia, Myeloid/therapy , Acute Disease , Bone Marrow Transplantation , Child , Humans , Immunophenotyping , Leukemia, Myeloid/physiopathology , PrognosisSubject(s)
Cerebral Infarction/diagnosis , Cerebral Infarction/etiology , Confusion/etiology , Mutism/etiology , Sinus Thrombosis, Intracranial/complications , Sinus Thrombosis, Intracranial/diagnosis , Thalamus/diagnostic imaging , Thalamus/pathology , Acute Disease , Adolescent , Female , Humans , Magnetic Resonance Angiography , Magnetic Resonance Imaging , Tomography, X-Ray ComputedABSTRACT
Spinal cord compression in Wilms' tumor is a rare event, generally caused by invasion of the canal by paraspinal lesions or metastatically involved vertebral bodies. This case report reviews the clinical presentation, radiologic evaluation, and emergent therapy in two cases of spinal cord compromise involving patients with widely metastatic Wilms' tumor. One of these is the only known report of intradural metastasis in a child with this malignancy. Both cases illustrate the importance of anticipating and rapidly responding to neurologic complications that may arise in patients with aggressively metastatic Wilms' tumor.